Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis

References

• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 655–61
   Google Scholar
• Paty D, Li D, UBC MS/MRI Study Group, IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a controlled multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43: 662–7
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial [The Copolymer 1 Multiple Sclerosis Study Group]. Neurology 1995;45:1268–76
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–94
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon ß-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–504
   PubMed Web of Science ®Google Scholar
• Li D, Paty D, UBC MS/MRI Analysis Research Group, PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing–remitting multiple sclerosis. Ann Neurol 1999;46: 197–206
   Google Scholar
• Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018–25
   PubMed Web of Science ®Google Scholar
• Polman C, O’Connor P, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006;354:899–910
   PubMed Web of Science ®Google Scholar
• Sackett DL. Evidence based medicine: how to practice and teach EBM, 2nd ed. Edinburgh: Churchill Livingstone; 2000. p. 113–8
   Google Scholar
• Pearce KA, Furberg CD, Psaty BM, Kirk J. Cost-minimization and the number needed to treat in uncomplicated hypertension. Am J Hypertens 1998;11:618–29
   PubMed Web of Science ®Google Scholar
• Mayne TJ, Whalen E, Vu A. Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions. J Clin Epidemiol 2006;59:217–23
   Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–7
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45: 1277–85
   Google Scholar
• Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 1999;18:53–63
   PubMed Web of Science ®Google Scholar
• European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491–7
   Google Scholar
• North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon-beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63: 1788–95
   Google Scholar
• Goodin DS. Disease-modifying therapy in MS: a critical review of the literature. I: analysis of clinical trial errors. J Neurol 2004;251(Suppl 5):v3–11
   Google Scholar
• Biogen Inc. summary basis of approval. FDA official document for license of interferon beta-1a (Avonex), Cambridge (MA), 1995 [online]. Available at http://www.fda.gov/cder/biologics/sba/ifnbbio051796s.pdf
   Google Scholar
• Goodin DS, Frohman EM, Garmany GP, Jr et al. Disease-modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169–78
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453–60
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496–506
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin D, Francis G, et al. Benefit of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67–74
   PubMed Web of Science ®Google Scholar
• Francis GS. Importance of benefit-to-risk assessment for disease-modifying drugs used to treat MS. J Neurol 2004;251(Suppl 5):v42
   Google Scholar
• Comi G, Filippi M, Wolinski JS. European/Canadian multicenter, double-blind randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290–7
   Google Scholar
• Ford C, Johnson KP, Brooks B, et al. Sustained efficacy and tolerability of Copaxone (glatiramer acetate) in relapsing– remitting multiple sclerosis patients treated for over 10 years. Mult Scler 2003;9:P485
   Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006;354:911–23
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukloencephalopathy. New Engl J Med 2006;354:924–33
   PubMed Web of Science ®Google Scholar
• Francis GS. Benefit–risk assessment of interferon-beta therapy for relapsing multiple sclerosis. Expert Opin Drug Saf 2004;3: 289–303
   PubMedGoogle Scholar
• Paty DW, Kappos L, Stam Moraga M, et al.; for the PRISMS Study Investigators. Long-term observational efficacy and safety follow-up of the PRISMS cohort. Mult Scler 2003;9: S138
   Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133–46
   Google Scholar
• Ebers GC, Paty DW. Natural history studies and applications to clinical trials. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F.A. Davis Company; 1997. p. 192–228
   Google Scholar
• Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004;62:51–9
   PubMed Web of Science ®Google Scholar
• Rice G, et al. European Committee for Treatment and Research in Multiple Sclerosis. Mult Scler 2001;7(Suppl 1):S1–137
   Google Scholar
• Goodin DS, Arnason BG, Coyle PK, et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:1332–8
   PubMed Web of Science ®Google Scholar